Cargando…

PD-L1 detection using (89)Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response

BACKGROUND: Programmed death-ligand 1 (PD-L1) expression in metastatic renal cell carcinoma (RCC) correlates with a worse prognosis, but whether it also predicts responsiveness to anti-PD-1/PD-L1 therapy remains unclear. Most studies of PD-L1 are limited by evaluation in primary rather than metastat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vento, Joseph, Mulgaonkar, Aditi, Woolford, Layton, Nham, Kien, Christie, Alana, Bagrodia, Aditya, de Leon, Alberto Diaz, Hannan, Raquibul, Bowman, Isaac, McKay, Renee M., Kapur, Payal, Hao, Guiyang, Sun, Xiankai, Brugarolas, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545669/ https://www.ncbi.nlm.nih.gov/pubmed/31155004 http://dx.doi.org/10.1186/s40425-019-0607-z

Ejemplares similares

A renal cell carcinoma tumorgraft platform to advance precision medicine
por: Elias, Roy, et al.
Publicado: (2021)

Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy
por: Mulgaonkar, Aditi, et al.
Publicado: (2023)

Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting
por: Lim, Jongdoo, et al.
Publicado: (2019)

Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma
por: Patel, Viral, et al.
Publicado: (2020)

Development and Histopathological Characterization of Tumorgraft Models of Pancreatic Ductal Adenocarcinoma
por: Garcia, Patrick L., et al.
Publicado: (2013)

Copper-67 radioimmunotheranostics for simultaneous immunotherapy and immuno-SPECT
por: Hao, Guiyang, et al.
Publicado: (2021)

A new tumorgraft panel to accelerate precision medicine in prostate cancer
por: Béraud, Claire, et al.
Publicado: (2023)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

Nivolumab treatment followed by atezolizumab induced encephalitis and neuropathy with antiganglioside antibodies
por: Watanabe, Shohei, et al.
Publicado: (2021)

Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue
por: Monsma, David J, et al.
Publicado: (2012)

Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts
por: ANDERSEN, NICHOLAS J., et al.
Publicado: (2015)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting
por: Kapur, Payal, et al.
Publicado: (2023)

Conventional Chemotherapy and Oncogenic Pathway Targeting in Ovarian Carcinosarcoma Using a Patient-Derived Tumorgraft
por: Glaser, Gretchen, et al.
Publicado: (2015)

Growth of malignant extracranial tumors alters microRNAome in the prefrontal cortex of TumorGraft mice
por: Kovalchuk, Anna, et al.
Publicado: (2017)

Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15 year experience and lessons learned
por: Gayed, Bishoy A., et al.
Publicado: (2016)

Differential expression and function of CAIX and CAXII in breast cancer: A comparison between tumorgraft models and cells
por: Chen, Zhijuan, et al.
Publicado: (2018)

Selective depletion of radiolabeled HER2-specific antibody for contrast improvement during PET
por: Khare, Priyanka, et al.
Publicado: (2021)

Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma
por: Schoenhals, Jonathan E., et al.
Publicado: (2021)

Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer
por: Aydin, Ahmet Murat, et al.
Publicado: (2017)

What is the role of nephrectomy following complete response to checkpoint inhibitors?
por: Woldu, Solomon L., et al.
Publicado: (2018)

(89)Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I
por: Chekol, Rufael, et al.
Publicado: (2018)

Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer
por: Ramagopalan, Sreeram, et al.
Publicado: (2021)

PET imaging of occult tumours by temporal integration of tumour-acidosis signals from pH-sensitive (64)Cu-labelled polymers
por: Huang, Gang, et al.
Publicado: (2019)

[(89)Zr]-Atezolizumab-PET Imaging Reveals Longitudinal Alterations in PDL1 during Therapy in TNBC Preclinical Models
por: Massicano, Adriana V. F., et al.
Publicado: (2023)

Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study
por: Hagens, Marloes HJ, et al.
Publicado: (2017)

Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis
por: Jauw, Yvonne W. S., et al.
Publicado: (2019)

Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET
por: Raavé, René, et al.
Publicado: (2019)

Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model
por: Escorcia, Freddy E., et al.
Publicado: (2018)

Automated light-induced synthesis of (89)Zr-radiolabeled antibodies for immuno-positron emission tomography
por: Klingler, Simon, et al.
Publicado: (2022)

Noise sensitivity of (89)Zr-Immuno-PET radiomics based on count-reduced clinical images
por: Somasundaram, Ananthi, et al.
Publicado: (2022)

Metastatic “Burned Out” Seminoma Causing Neurological Paraneoplastic Syndrome—Not Quite “Burned Out”
por: Freifeld, Yuval, et al.
Publicado: (2018)

Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high‐risk prostate cancer patients with worse survival following radiation therapy
por: Jacobs, Corbin, et al.
Publicado: (2015)

(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
por: Miedema, Iris H.C., et al.
Publicado: (2023)

Imaging the L-Type Amino Acid Transporter-1 (LAT1) with Zr-89 ImmunoPET
por: Ikotun, Oluwatayo F., et al.
Publicado: (2013)

Zr-89 Immuno-PET Targeting Ectopic ATP Synthase Enables In-Vivo Imaging of Tumor Angiogenesis
por: Park, Bok-Nam, et al.
Publicado: (2019)

(89)Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe
por: Fung, Kimberly, et al.
Publicado: (2020)

(89)Zr-DFO-Isatuximab for CD38-Targeted ImmunoPET Imaging of Multiple Myeloma and Lymphomas
por: Herrero Alvarez, Natalia, et al.
Publicado: (2023)

Chemo brain or tumor brain - that is the question: the presence of extracranial tumors profoundly affects molecular processes in the prefrontal cortex of TumorGraft mice
por: Kovalchuk, Anna, et al.
Publicado: (2017)

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
por: Alonso-García, Miriam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lfn68kcocr18kacu1367dj2p30